Drug-Drug Interactions

Drug–drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have bee...

Full description

Saved in:
Bibliographic Details
Format: eBook
Language:English
Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
Subjects:
ISBN:9783036520353, 3036520368, 303652035X, 9783036520360
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Drug–drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs with CYP remains very important in drug interactions but, recently, other important mechanisms have also been studied as contributing to drug interaction including transport- or UDP-glucuronyltransferase as a Phase II reaction-mediated DDI. In addition, novel mechanisms of regulating DDIs can also be suggested. In the case of the substance targeted for interaction, not only the DDIs but also the herb–drug or food–drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or studies on new mechanisms will be very helpful for preventing the side effects of the patient taking these drugs. This Special Issue aims to highlight current progress in understanding both the clinical and nonclinical interactions of commercial drugs and the elucidation of the mechanisms of drug interactions.
AbstractList Drug–drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs with CYP remains very important in drug interactions but, recently, other important mechanisms have also been studied as contributing to drug interaction including transport- or UDP-glucuronyltransferase as a Phase II reaction-mediated DDI. In addition, novel mechanisms of regulating DDIs can also be suggested. In the case of the substance targeted for interaction, not only the DDIs but also the herb–drug or food–drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or studies on new mechanisms will be very helpful for preventing the side effects of the patient taking these drugs. This Special Issue aims to highlight current progress in understanding both the clinical and nonclinical interactions of commercial drugs and the elucidation of the mechanisms of drug interactions.
BookMark eNotj81KQzEQRgMqqPVu3QjiC0RnMkluspRqtVDopq7L5E-KkkhT399bdXM-OIsD36U4ra1mIW4R7ok8PITWProfnSQJZI1UEyWciGFydDSTMHQuht53AQxoBG3wQlw_7b_f5RF3y3rIe46HXav9SpwV_ux5-N-ZeFs8b-avcrV-Wc4fVzLgiCAL64DE5CDamMBGVqM36EtWmtm7rBmQvAEuJSkX0aTkVAGLNoXkAs3EzV-38Veu29T498h2tG5E-gG-oDyr
ContentType eBook
DBID V1H
DOI 10.3390/books978-3-0365-2036-0
DatabaseName DOAB: Directory of Open Access Books
DatabaseTitleList
Database_xml – sequence: 1
  dbid: V1H
  name: DOAB: Directory of Open Access Books
  url: https://directory.doabooks.org/
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Editor Kim, Dong Hyun
Lee, Sangkyu
Editor_xml – sequence: 1
  fullname: Kim, Dong Hyun
– sequence: 2
  fullname: Lee, Sangkyu
ExternalDocumentID 76871
GroupedDBID ALMA_UNASSIGNED_HOLDINGS
HVQEU
V1H
ID FETCH-LOGICAL-b1710-fa4b13a380c6cd06ca279519fe24aa98e4a013950affd28c15dd82f0616dbd8b3
IEDL.DBID V1H
ISBN 9783036520353
3036520368
303652035X
9783036520360
IngestDate Tue Oct 07 23:40:34 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b1710-fa4b13a380c6cd06ca279519fe24aa98e4a013950affd28c15dd82f0616dbd8b3
OpenAccessLink https://directory.doabooks.org/handle/20.500.12854/76871
PageCount 242
ParticipantIDs oapen_doabooks_76871
PublicationCentury 2000
PublicationDate 2021
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – year: 2021
  text: 2021
PublicationDecade 2020
PublicationPlace Basel, Switzerland
PublicationPlace_xml – name: Basel, Switzerland
PublicationYear 2021
Publisher MDPI - Multidisciplinary Digital Publishing Institute
Publisher_xml – name: MDPI - Multidisciplinary Digital Publishing Institute
SSID ssib050410451
Score 2.2110996
Snippet Drug–drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known...
SourceID oapen
SourceType Publisher
SubjectTerms (‒)-sophoranone
1A2
2B6
2C19
2C8
2C9
2D6
3A4
ADME
adverse drug reactions
biflavonoid
Biology, life sciences
chronic kidney disease
competitive inhibition
computational prediction
CYP
CYP1A1
CYP1A2
CYP2C9
CYP2D6
CYP3A
CYP3A4
cytochrome P450
cytochromes P450
DDI
Dexamethasone
drug interaction
drug interactions
drug metabolism
drug transporter
drug-drug interaction
drug-drug interactions
expression
fexofenadine
gepants
high plasma protein binding
in silico
in vitro
in vivo
inhibitor
ixazomib
Ketoconazole
lasmiditan
Lexicomp
low permeability
Loxoprofen
Mathematics and Science
mechanism-based inhibition
metabolic DDI
metabolism
migraine
monoclonal antibodies
non-competitive inhibition
O-desmethyltramadol
OATP1B1
OATP1B3
organic anion transporting polypeptide 1A2 (OATP1A2)
P-glycoprotein (P-gp)
P450
pharmacokinetics
physiologically-based pharmacokinetics
plasma concentration
polypharmacy
potent inhibition
QSAR
Reference, Information and Interdisciplinary subjects
regulation
Research and information: general
Rumex acetosa
selamariscina A
signal detection algorithms
spontaneous reporting systems
subset analysis
substrate
systemic exposure
tadalafil
ticagrelor
tissue-specific
tramadol
tyrosine kinase inhibitors
ubiquitination
uridine 5′-diphosphoglucuronosyl transferase
Title Drug-Drug Interactions
URI https://directory.doabooks.org/handle/20.500.12854/76871
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV25TgMxELWihIIKUIi4lYJ2ie-1ayBKFVEA2i4aX4hmg3Lw_Xi8BAWJimYl7zYe2Wu_Z897Q8htks7qoGWevDZV0gRbGahD_t19kDYapxmUYhP1fG6axj71iNlpYbqFfIlZzUtAnLku1_md5UBm6neKoiOCUXKSgTKKxweZ4WikXa9stptJikqGxiko5shLtOJUqGavoU3nvfPzUfxua9qJiYWwdFJ60WUR0JIThh6-FAskwUds93aj6dH_4zgmg4jqhhPSi-2QjB5W27cKH-NyMtiJHNan5GX6-Hw_q74LJVSOZYRQJZCOCRCGeu0D1R54nZGTTZFLAGuiBER6ikJKgRvPVAiGp7yV6-CCcWJE-u2yjWdkzEJ0YMC6mHEGz_w40yMODKKQdaYW_pwMS9iLXViL0v2Lv19fkkOOOSDlyOKK9DerbbwmB_5z875e3ZQh-wKaro5_
linkProvider Open Access Publishing in European Networks
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=book&rft.title=Drug-Drug+Interactions&rft.date=2021-01-01&rft.pub=MDPI+-+Multidisciplinary+Digital+Publishing+Institute&rft.isbn=9783036520353&rft_id=info:doi/10.3390%2Fbooks978-3-0365-2036-0&rft.externalDBID=V1H&rft.externalDocID=76871
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=9783036520353/lc.gif&client=summon&freeimage=true
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=9783036520353/mc.gif&client=summon&freeimage=true
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=9783036520353/sc.gif&client=summon&freeimage=true